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ABSTRACT 
Autism Spectrum Disorders (ASD) are a group of developmental disorders caused 
by environmental and genetic factors. Diagnosis is based on behavioral and 
developmental signs detected before 3 years of age with no reliable biological 
marker. The purpose of this study was to evaluate the potential use of a 2D NMR-
based approach to express the global biochemical signature of autistic individuals 
compared to normal controls. This technique has greater spectral resolution than 
to 1D 1H NMR spectroscopy, which is limited by overlapping signals. The urinary 
metabolic profiles of 30 autistic and 28 matched healthy children were obtained 
using a 1H-13C NMR-based approach. The data acquired were processed by 
multivariate orthogonal partial least-squares discriminant analysis (OPLS-DA). 
Some discriminating metabolites were identified: b-alanine, glycine, taurine and 
succinate concentrations were significatively higher, and creatine and 3-
methylhistidine concentrations were lower in autistic children than in controls. We 
also noted differences in several other metabolites that were unidentified but 
characterized by a cross peak correlation in 1H-13C HSQC. Statistical models of 1H 
and 1H-13C analyses were compared and only 2D spectra allowed the 
characterization of statistically relevant changes [R2Y(cum) = 0.78 and Q2(cum) = 
0.60] in the low abundance metabolites. This method has the potential to 
contribute to the diagnosis of neurodevelopment disorders but needs to be 
validated on larger cohorts and on other developmental disorders to define its 
specificity. 
Keywords HSQC NMR spectroscopy . Autism spectrum disorders . Urinary 
metabolites . OPLS-DA . Metabolomics
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1. Introduction 
Autistic disorder (AD), Asperger syndrome (AS) and pervasive developmental 
disorder-not otherwise specified (PDD-NOS) are collectively termed autism 
spectrum disorders (ASD). The prevalence of ASD appears to be increasing (1 in 
110 children in 2009) [1] without identification of the etiology of this increase [2-
5]. Autism is diagnosed in infancy between the second and the third years of life 
[6]. Autistic children are particularly characterized by a behavioral triad of impaired 
communication, impaired social interaction, and restricted and repetitive interests 
and activities, as listed in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV). Diagnosis is in part made clinically by subjective analyses 
based on perceived behaviors in the patient, and is thus dependent on the 
expertise of those administering the tests. Several studies have explored the 
possibility of using metabolite profiles to contribute to the diagnosis of 
developmental disorders [7]. As autism disease has many suspected causes 
including dysfunctions of the gastrointestinal, immunologic and/or neurologic 
systems, with some markers showing ubiquitous distribution, it could be assumed 
that urine metabolites profile could help in the diagnosis and in the 
pathophysiological mechanisms knowledge of the autism pathology [8, 9]. 
Furthermore urine represents a sample of choice as it is easily and non-invasively 
collected, that is of particular importance when exploring the autistic population 
and so we explored in this paper through 2D NMR analysis, the metabolic 
signature of patients’ urine compared to those of healthy subjects in order to 
identify potential biomarkers useful for the early diagnosis of ASD.
Metabolomics approaches offer the possibility of assessing metabolic 
signatures linked with genetic and environmental factors. These approaches have 
previously been applied for disease diagnosis, therapeutics, functional genomics 
and toxicology studies [10, 11]. The most commonly used analytical platforms to 
identify and quantify metabolites are gas chromatography combined with mass 
spectroscopy (GC-MS) and nuclear magnetic resonance spectroscopy (NMR) 
[12-14]. 1H NMR spectroscopy is a powerful, rapid analytical method providing a 
metabolic profile and has already yielded promising results in diagnosing 
neuropsychiatric disorders such as autism [7]. Unfortunately, a relatively small 
number of metabolites can be identified by this method, as signals were disturbed 
by spectral overlap. To improve the ability to identify a mixture of components by 
NMR, two dimensional NMR (2D-NMR) spectra may be of value. Heteronuclear 
single quantum coherence (1H-13C HSQC)-based NMR provides higher resolution 
than classical 1D-NMR-based approaches [15-18]. The 2D-NMR HSQC results in 
a 2D map in which the two axes correspond to a 1H-NMR and a 13C-NMR 
spectrum. Furthermore, 2D-NMR reduces the problem of spectral overlap by peak 
dispersion and results in a higher proportion of resolved peaks, thus increasing 
metabolite specificity (for example, between 30 to 50 metabolites can be 
characterized by 1H NMR [19] compared to more than 150 by HSQC [20] in urine 
samples). This technique has recently been used in several studies [21-23] to 
determine plant fingerprinting [17] and animal systems [24], and in human 
metabolic studies [25, 26] but, to our knowledge, the study reported here is the 
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first 2D HSQC-based NMR study applied to the screening of urine samples of ASD 
patients and controls.
This report evaluates a 2D-NMR-based approach to explore the metabolic 
profile of urine in an ASD context. As part of this study, statistical analysis 
methods [principal component analysis (PCA), partial least squares discriminant 
analysis (PLS-DA) and orthogonal partial least squares discriminant analysis 
(OPLS-DA)] were used to reveal metabolites that discriminated between ASD and 
control populations.
2. Materials and Methods 
2.1. Sample collection
Between 2008 and 2010, urinary samples were collected in sterile vials 
untreated with preservative from children aged 6-14 years (mean 8 years) with 
ASD living in France (n = 30; male 80%, female 20%) and control children (n = 28; 
male 61%, female 39%) aged 6-9 years (mean 8 years). All study participants 
provided informed consent. The severity of autism was assessed according to the 
International Classification of Diseases 10th Edition during medical consultations in 
three French autism centers [Tours (n = 11), Montpellier (n = 15), and Orléans (n 
= 4)] and twenty-eight urine samples from healthy volunteers from Tours. Each 
urine sample was aliquoted in a 1.5 mL Eppendorf tube and stored at -80°C 
immediately after collection until analysis.
2.2. NMR study
2.2.1. Sample preparation  
Urine samples were thawed out at room temperature, and centrifuged (at 
3000 g) for 10 min. Samples were prepared by mixing 500µL of urine supernatant, 
100µL of D2O solution with internal reference [3-trimethylsilylpropionic acid (TSP), 
0.05 wt% in D2O] and 100µL of phosphate buffer to obtain pH = 7.4 ± 0.5. 
Samples then were transferred into conventional 5-mm NMR tubes for 1H-13C NMR 
analysis.
2.2.2. NMR spectroscopy experiments
All NMR experiments were performed at 298 K on a Bruker DPX Avance 
spectrometer operating at 300 MHz, using a double resonance (1H-13C) 5-mm 
(Bruker SADIS, Wissembourg, France). 
Standard one dimensional (1D) NMR spectra were acquired using a “zgcppr” 
pulse program in the Bruker library. 32K data points with 16 scans were acquired 
using a spectral width of 3001 Hz. Water suppression was achieved during the 
relaxation delay of 2 s using a waltz 16 decoupling sequence with a decoupling 
power of 55 dB during the acquisition period. All samples were automatically 
tuned, matched and shimmed.
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All sensitivity-enhanced 1H-13C HSQC spectra were collected using an 
“hsqcetgp” pulse program in the Bruker library with 512x128 data points using 32 
scans per increment, with acquisition time of 0.0852 s in t2 with a relaxation time 
of 2.5 s. The spectral widths were set at 20 ppm in the proton dimension and 250 
ppm in the carbon. 13C-decoupling during acquisition was performed using GARP 
sequence (pulse length 1 ms) applied during t2. The coupling constant 
1JC-H was 
fixed at 145 Hz, using a shine shaped gradient of 80, 20.1, 20.1, and a homospoil 
gradient pulse recovery delay of 200 ms. Each experiment lasted 3h.
2.2.3. Data processing
1D and 2D spectra were processed using MestReNova version 7.1.0 software 
(Mestrelab Research, S.L., Santiago De Compostela, Spain). After Fourier trans-
formation of each FID, 1D spectra were phased manually. All urine spectra were 
normalized with an external reference [3-trimethylsilylpropionic acid (TSP), 0.05 wt
% in D2O]. TSP served as a chemical shift reference set at 0 ppm and as a quant-
itative reference signal. Predefined 2D integration regions were established manu-
ally from several spectra (all cross-peaks presented in 6 controls and in 6 ASD 
samples were cumulated). Once this predefined list had been established, HSQC 
cross-peaks were automatically referenced to the TSP signal, and then were auto-
matically integrated. TSP integration was set at the same value for each spectrum. 
The region from 4.45 ppm to 5.15 ppm was removed to eliminate baseline effects 
due to the water signal. The previously established list contained 163 different 13C 
cross-peaks between 10 and 150 ppm. 
The signals were assigned, as far as possible, by comparison with the 
chemical shifts given by the freely available Metabominer software [20] or from 
literature data [25], with tolerances of 0.05 ppm (1H) and 0.1 ppm (13C). 
Identification was achieved if there was only one candidate in the database within 
the specified tolerances for an observed peak. 
All 1D spectra were corrected for phase distortion and the baseline was cor-
rected manually for each spectrum. Two methods of integration were done. The 
first was an automated “bucketing” with a fixed width of 0.04 ppm per bin. The 
second method was called “rationalized” integration: 1D proton spectra were pre-
pared as a data matrix by bucket integration from the list obtained from the pre-
defined 2D integration regions. From this predefined 2D auto-integration region, 
the f2 listing (corresponding to 1H dimension) was retained to define the pre-
defined 1D 1H f1 auto-integration region. Duplicate buckets having the same 1H 
chemical shift (in f2 listing) were removed. In regions where no 1H-13C cross-
peaks were observed, buckets with constant 0.04 ppm width were defined. As the 
predefined 2D auto-integration region was established manually taking into ac-
count each individual signal, allowing signals with different larger shifts, the 186 
resulting buckets were so defined with variable widths (but with a mean of 0.05 
ppm). 
2.3. Statistical Methods  
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The intensity of all peaks for all urine samples were studied by multivariate 
statistical methods, following protocols given in the literature [27, 28]. 
2.3.1. Multivariate analysis
Multivariate analysis was performed using Simca-P+-12 software (version 
12.0, Umetrics, Umeå, Sweden). Unit variance (UV) scaling, pareto scaling (Par), 
obtained by dividing each variable by the square root of its standard deviation, or 
logarithmic transformation, which is a nonlinear conversion, were used to minimise 
the impact of noise or high variability of the variables [29]. Principal component 
analysis (PCA) [30] was first performed as an unsupervised clustering to identify 
the similarity or the differences between sample profiles. Grouping, trends and 
outliers were revealed from the scatter plot. If these outliers were also detected in 
the distance to model plot (DModX), which was based on residual variance of the 
model, they were rejected from the model, and a PCA model was rebuilt. In order 
to identify subsets (linear combinations) of metabolic features associated with a 
specific sample class (ASD or control), partial least squares (PLS) analysis was 
used as supervised clustering. PLS derives latent variables which describe the 
maximum proportion of covariance between measured data (X matrix) and the 
response variable (Y matrix) [31]. Orthogonal partial least squares discriminant 
analysis (OPLS-DA), also used for discrimination, is a refinement of this approach: 
variation in the data measured is partitioned into 2 blocks, one containing 
variations that correlate with the class identifier (ASD or control) and the other 
containing variations that are orthogonal to the first block and thus do not 
contribute to discrimination between the defined groups [32]. The quality of the 
models was described by the cumulative modeled variation in the X matrix 
R2X(cum), the cumulative modeled variation in the Y matrix R2Y(cum), and the 
cross validated predictive ability Q2(cum) values. Models were rejected if they 
presented complete overlap of Q2 distributions [Q2(cum) < 0] or low classification 
rates [Q2(cum)< 0.05 and eigenvalues should be > 2]. The features with variable 
importance on projection (VIP) values and regression coefficients 
!CoeffCS!1!!lower than 0.35 were deleted and evaluated again. A number of 
variables were obtained from PLS-DA and OPLS-DA that were responsible for the 
difference between ASD and control urine samples for VIP value > 1.0.  
One of the main problems with PLS-DA is the data overfitting occurring if 
the algorithm picks up random noise to real signals. To validate the model, the 
data are divided into 7 parts, a model is built on 6/7th of data left in, and the left 
out data are predicted [33]. The predicted data are then compared with the 
original data and the sum of squared errors calculated for the whole dataset. This 
is converted into Q2, which is an estimation of the predictive ability of the model. 
The model was thus considered sufficiently well guarded against overfitting and 
validated after 200 random permutation tests [34] as the Q2 line intercepted the Y 
axis at a negative value. 
Furthermore, we also performed PLS-DA with autoscaling normalization 
which is very similar to pareto scaling using the freely available web-based 
software called MetaboAnalyst [20]. 
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2.3.2. Univariate analysis
Student’s t-test was performed using MetaboAnalyst [20] for all metabolites 
with a VIP >1.0. The ratio of the peak areas of these metabolites to that of 
creatinine was calculated and a non-parametric test was performed with the 
critical p-value set at 0.05 [28, 35].
3. Results 
3.1. NMR Experiments
A typical 2D HSQC spectrum of urine fitted with the 1H-NMR sub-spectrum 
on its side is shown in Figure 1. The 2D-HSQC analysis provided 163 cross-peaks 
integrated and normalized with an external reference (TSP). 
Fig. 1. 1H-13C HSQC NMR spectrum of urine at 300 MHz, with a typical 1H 
spectrum as external spectrum, showing the assignment of the significant 
metabolites responsible for discriminating children with ASD from non-autistic 
children when possible. Only VIP >1 obtained by OPLS-DA (model 4) were 
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distinguished. Peaks increased in the ASD group are in red, and those decreased 
are in green.
3.2. Statistical studies from 2D HSQC NMR data – choice of pre-treatment 
technique
PCA was performed as unsupervised clustering and we did not identify any 
particular similarity or any great differences between sample profiles (no outliers 
were eliminated). Discriminating metabolites were proposed using PLS-DA and 
OPLS-DA from one predictive and two or more orthogonal components. We have 
studied the impact of pre-treatment of the NMR data before multivariate analysis 
using unit variance (UV), pareto (Par), and autoscaling. In parallel, the impact of 
log-based transformation was performed.
Table 1 
Summary of statistical values of PLS-DA and OPLS-DA of 1H-13C HSQC with 
different data scaling. The different cumulated modeled variations in X [R2X(cum)) 
and Y (R2Y(cum)] matrices on spectral datasets and predictability of the model 
(Q²) are given [observations (N)=58].
Scaling/transformation R2X R2X (cum) R2Y (cum) Q2 (cum)
Model 1 a UV 0.0533 0.290 0.784 0.399 
Model 2 b: UV 0.0488 0.271 0.782 0.602
Model 3 c Pareto 0.0593 0.598 0.700 0.428
Model 4 d log transformed, UV scal-
ing
0.0525 0.155 0.758 0.544
a: PLS-DA, from 3 components, Variables X=63
b OPLS-DA, Variables X=43, 2 orthogonal projections
c: OPLS-DA, Variables X=54, 3 orthogonal projections
d: OPLS-DA, , Variables X=44, 1 orthogonal projection
Table 1 summarizes the features of the different models. The processed 
variables are represented by X (metabolites), Y variables represent the different 
children’s urine samples. R2X(cum) is the sum of predictive orthogonal variations 
in X that is explained by the model. From the predictive variation between X and Y 
given by R2X(cum), models 1 and 2 with the same scaling (UV) interpreted around 
30% of the total variation in X (0.29 and 0.27, respectively, Table 1). The amount 
variation that could not be explained by the model might originate from the noise. 
This variation was minimized by Pareto scaling and for model 3 is expressed by 
the formula [36]: 1 - R2X - R2X(cum) = 1 - 0.0593 - 0.598 = 0.343, as noise 
could account for 34% in this analysis. The quality of the models was expressed 
by R2Y(cum) and Q2(cum) values, where R2Y(cum) is defined as the proportion of 
variance in the data explained by the models and indicates goodness of fit. All the 
models explained around 70% to 80% of the variations in the different peaks. A 
high Q2(cum) value [Q2(cum) > 0.5] indicated good predictivity. Table 1 shows 
that noise was minimized by Pareto scaling [R2X(cum) higher in models 3], but 
this pre-treatment led to lower predictability [Q2(cum) = 0.43]. As UV scaling 
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seemed to be the best scaling in our study (confirmed by analysis of variance CV-
ANOVA, p-value = 7.773.e-009, see supporting information), we focused on this 
method. Thus the OPLS-DA cross-validated score plots for model 2 (Fig. 2) 
showed discrimination between the two populations. 
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Fig. 2. Scatter plot of OPLS-DA scores of the first principal component obtained 
from 1H-13C HSQC NMR spectra of urine samples, model 2 (UV scaling, Table 1) 
[(n=30 ASD samples (red dot), n=28 control samples (black box) with R2Y(cum) = 
0.78 and Q2(cum) = 0.60].
3.3. Statistical studies from 2D HSQC NMR data – Analysis of model and 
identification of important features
From PLS-DA or OPLS-DA, the most highly contributing metabolites in the 
discrimination of the 2 populations were screened recording to the variable 
importance on projection (VIP) values >1.0. The effect of a data pre-treatment 
method on the ranking of the metabolites is presented in Table 2. For example, a 
signal characterized by peak ID 123 was identified as the most relevant for PLS-
DA and OPLS-DA methods using UV scaling, or log transformed, but was the 6th 
rank with Pareto scaling (Table 2, model 3). As another example, pyroglutamic 
acid (peak ID 46) was the 6th highest metabolite on OPLS-DA UV scaling, while by 
log transformation, pyroglutamic acid appeared after the first 15 most relevant 
metabolites when applying rank scaling. The differences could be due to the 
magnitude of the fold change (or relative standard deviation) of some metabolites 
present that was balanced by nonlinear log transformation. Furthermore, a PLS 
model, with autoscaling normalization, was also tested and provided the same VIP 
as shown in Table 2 (model 5). 
The loading scatter plot in Figure 3 shows which variables led to 
discrimination between ASD and control children in model 2 (Table 1), the chosen 
model.  
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Fig. 3. pq loading plot of OPLS-DA model 2 (Table 1): scatter Plot of the X- and 
Y-loadings (p and q). This plot shows how the responses (Y's) varied in relation to 
each other, i.e. which provided similar information and their relationship to the 
terms of the model. Two tendencies could be seen. Peaks framed in red were 
higher levels in ASD urine, and peaks framed in green were lower. 
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Table 2 
Analysis of urinary metabolites in children: cross-peak and chemical shift values for 2D 1H-13C HSQC spectra and 
variable importance (VIP values) for different statistical studies.
Pea
k
1H 
(pp
m)
13C 
(ppm)
Differentiatio
n for ASD 
samples
Potential 
Assignment
PLS-DA.VIP coeff OPLS-DA.VIP coeffa
UVa
Model 1
Autoscalingb
Model 5
UV
Model 
2
Pareto
Model 
3
log 
transf.,U
V
Model 4
123 4.01 56.67 ↓
Cystathionine/Cysti
ne c
1.77 2.28 (0.0082) 1.66 1.43 1.66
157 7.47 115.5            ↑ Indican/Serotonin c 1.60 2.18 1.58 <1 1.60
56 2.67 48.35            ↑ Citric acid 1.54 1.94 (0.0464) 1.56 2.08 1.31
134 4.24 47.08            ↑ ND 1.47 2.12 (0.0570) 1.54 1.77 1.50
100 3.75 34.76 ↓ 3-Methylhistidine 1.39 1.89 (0.0438) 1.37 2.36 1.33
46 2.40 28.51 ↓ Pyroglutamic acid 1.32 1.86 1.34 - 1.04
116 3.94 56.81 ↓ Creatine 1.41 1.85 (0.0447) 1.34 2.79 1.04
82 3.49 31.99            ↑
3-Methylxanthine/
…. c
1.30 1.84 1.33 <1 1.41
78 3.46 46.57            ↑
Homovanillic ac/4-
h yd r o x y p hen y l 
acetic c
1.29 1.82 1.32 <1 1.20
11
131 4.14 45.36            ↑ ND 1.23 1.76 1.28 <1 1.31
138 5.56
112.6
5
           ↑ ND 1.21 1.74 1.26 <1 -
47 2.42 36.96            ↑ Succinic acid 1.28 1.73 - <1 1.22
128 4.09 85.92            ↑ Cytidine/ c 1.17 1.65 1.20 1.21 <1
52 2.51 36.23            ↑ b-alanine 1.15 1.60 - <1 1.22
80 3.46 49.88 ↓ ND 1.15 1.58 1.15 <1 1.08
93 3.65 34.72            ↑ ND 1.14 1.58 1.14 1.02 0.97
77 3.43 38.34            ↑
Taurine/dihydrourac
il c
1.11 1.32 0.95 <1 1.30
55 2.61 37.75            ↑ ND - 1.55 (0.0478) - <1 <1
85 3.56 44.40            ↑ Glycine 1.08 1.52 - 1.46 1.03
114 3.92 36.57            ↑ ND 1.03 1.44 1.05 0.99 <1
62 3.13 39.81 ↓
Tyrosine 
/Phenylalanine/…c
1.10 1.44 1.05 <1 1.03
145 7.14
120.1
2
↓ Histidine 1.07 1.39 (0.0173) 1.00 <1 1.10
150 7.21
125.0
0
↓
Tryptophan/Indolac
etic acid c
1.04 1.30 (0.0343) 0.94 <1 <1
70 3.28 50.25            ↑ Taurine 1.02 0.90 <1 <1 -
12
153 7.30
125.6
2
           ↑ Indican/… c 0.98 1.37 1.00 <1 1.05
(↑ ) denotes an increased concentration for ASD population, (↓): decreased
(ND) data not determined
(-) denotes not present in the model
a: Magnitude of variation of VIP with a threshold of 1.0 obtained using Simca-P+ software.
b: VIP values obtained from MetaboAnalyst software, p-value given in brackets and italics after ratio of peak areas 
to creatinine .
c denotes ambiguity in the characterization 
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The results of discriminating biomarkers were validated using univariate 
analysis (Student’s t-test) calculated as the ratio of the selected urinary metabolite 
peak area to creatinine. We obtained 7 cross-peaks (Table 2) with significant 
differences at p < 0.05. 
3.4. Targeted segmentation of 1H-NMR spectra using a priori 2D HSQC cross-
peaks
As NMR spectral data from a 600 MHz spectrometer were statistically more 
relevant compared to our spectral data obtained at 300 MHz, we expected that 
from results obtained from 2D study, we could improve the analyse of 1H NMR 
data obtained on a low field spectrometer. Once the 2D HSQC NMR spectra had 
been analyzed by multivariate data analysis, targeted metabolic segmentation was 
performed on the 1H NMR spectra to improve the usual automated 1H NMR 
segmentation. The 1D segments were established using the 2D integration zones, 
taking into account each individual signal allowing signals with larger shifts. This 
resulted into variable width integration areas, with a mean width of 0.05 ppm. 
PLS-DA showed that this “rational” segmentation, which was more time 
consuming, resulted in a slightly better model (Table 3, model 6), 47% of the 
proportion of variance of the data obtained from variable widths being explained 
by PLS-DA compared to 42% [R2Y(cum)= 0.42] obtained from the automated 
fixed width of 0.04 ppm per bin. The cross-validated predictive ability Q2(cum) 
values were slightly better for the “rationalized” method compared to the 
automated “bucketing” method (0.24 compared to 0.17, respectively). Even with 
“rationalized” method, compared to Yap et al.’s study [7], PLS-DA study of 1H 
NMR spectral data was statistically more relevant using a 600 MHz spectrometer 
compared to our spectral data obtained at 300 MHz [R2Y(cum) = 0.72 and 
Q²(cum) = 0.33 [7] compared to 0.475 and 0.24, respectively, in model 6 (Table 
3)].
To improve the discrimination analysis of 1H NMR-300 MHz data on targeted 
metabolites, OPLS-DA was performed following the same pre-treatment 
procedure as the 2D study. For this 1D study, the quality of OPLS-DA with regard 
to R2X(cum) and R2Y(cum) values showed that UV (Table 3, model 7) and pareto 
(Table 3, model 8) scaling led to the same discrimination [0.55 ± 0.01 for 
R2X(cum) and 0.46 for R2Y(cum)], log transformation (Table 3, model 9) provided 
a weaker result with R2Y(cum) = 0.40. In terms of the predictability of the different 
models, UV scaling seemed to be the best with Q2(cum) = 0.32 compared to less 
than 0.20 for the other two OPLS-DA (Table 3, models 8 and 9). Using the same 
NMR spectrometer (300 MHz), the multivariate analysis on targeted metabolites 
was clearly better for 2D NMR analysis compared to 1D NMR analysis. With UV 
scaling, model 7 only explained 46% of the variations in the different peaks 
[R2Y(cum) = 0.458] compared to 78% for model 2 (Table 1) in the 2D analysis. 
The predictability regarding Q²(cum) values was also much better in the 2D study 
(0.59 for model 2 compared to 0.32 in model 7). 
Table 3 
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Summary of PLS-DA and OPLS-DA of 1H statistical values with different data 
scaling. The different cumulated modeled variations in X [R2X(cum)] and Y 
[R2Y(cum)] matrix on spectral datasets and predictability of the model (Q²) are 
given [observations (N)=58].
Scaling/transformation R2X R2X (cum) R2Y (cum) Q2 (cum)
Model 6 a UV 0.173 0.539 0.475 0.24 
Model 7 b: UV 0.086 0.561 0.458 0.32
Model 8 c Pareto 0.0505 0.543 0.462 0.193
Model 9 d log transformed, UV 
scaling
0.123 0.755 0.406 0.217
a: PLS-DA, from 3 components, Variables X=51
b OPLS-DA, Variables X=43, 2 orthogonal projections
c: OPLS-DA, Variables X=65, 2 orthogonal projections
d: OPLS-DA, Variables X=34, 3 orthogonal projections
4. Discussion
A metabolomics approach using 2D-NMR is a powerful tool to analyze rich 
biological fluid such as urine. A 2D-NMR spectrum provides more information 
compared to a 1D-NMR spectrum as one peak is obtained for each pair of 
coupled nuclei, whose two coordinates are the chemical shifts of the two coupled 
atoms. When a HSCQ sequence is used, correlation peaks show the connectivity 
between carbons (13C) and their attached protons. Although a 2D-NMR strategy is 
more time consuming than 1H-NMR, it provides a more detailed picture of the 
matrix composition especially in resonance areas where overlapping occurs. Fewer 
overlapping problems are seen in 13C-NMR spectra because of the larger chemical 
shift dispersion (200 ppm compared to 10 ppm for 1H). In 2D spectra, peaks from 
low abundance structures are better resolved from neighbouring peaks belonging 
to more abundant structures, and thus can be characterized when 1D 1H-NMR 
analysis cannot resolve overlapping signals because the more abundant structures 
may hide less abundant metabolites. 
Metabolomics studies using 1H NMR-based applications have shown 
variations in urinary metabolic profiles between children with and without ASD [7]. 
As this previous study analyzed around 20 metabolites, we expected that 2D 
spectra would improve the identification of statistically relevant changes in the 
abundance metabolites. Data processing methods are highly dependent on the 
pre-treatment technique of these values. Variations between samples can 
generally be classified into “technical” or “biological” variance, but the impact of 
technical variability should be minimized and discrimination of noise from useful 
biological data obtained. Several types of scaling are usually used: UV, Par, and 
autoscaling. UV means that the variable is centered and scaled from the standard 
deviation of the variable. The combination of scaling and mean centering is called 
autoscaling in MetaboAnalyst software [each descriptor (with high or small 
intensity) is weighted equally] [37]. In Par scaling, which is similar, the variance 
changes from variable to variable, but the range of variance across each spectrum 
is much reduced from the initial unscaled data (weak values being scaled up while 
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the stronger intensities are scaled down). The choice of pre-treatment methods 
depends on several factors (numbers of samples, magnitude of concentration, 
similarities, etc), and emphasizes different aspects of the data. As each method 
has its own merits and drawbacks, and as, to our knowledge, no-one has 
determined what the best pre-treatment is for NMR-based data in children’s urine, 
we studied the impact of these scaling methods on identification of biomarkers. 
We found that pre-treatment affected the ranking of the data, but the listing 
without ranking for all VIP >1.0 was almost the same whatever the pre-treatment 
used. UV scaling seemed to be the best scaling method for our study. As OPLS-
DA is recommended to obtain a clearer and more straightforward interpretation 
[37], we focused on this method. As UV scaling is usually used, and in order to 
be able to compare our results with other studies [7], and as the types of other 
scaling did not lead to better interpretation, we focused on results obtained from 
OPS-DA using UV scaling (Table 1, model 2). 
Factors such as disease, drugs and diet are known to modify individual 
metabolites concentrations [38, 39]. Furthermore, the number of samples studied 
was too limited to obtain any real statistical characterization of a general 
population of children. Nevertheless, it may be useful to explore whether certain 
tendencies (characterized or unknown peaks) can be detected in the samples 
studied. Few untargeted metabolomics studies have been performed on urine 
samples to identify biomarkers of ASD [7, 40]. A previous OPLS-DA (UV scaling) 
showed that the profile of urinary metabolites was not so easy to analyze by 1H 
NMR spectroscopy [weak R2Y(cum) = 0.275 and Q2(cum) = 0.15] [7]. Using 2D 
HSQC analysis we obtained a group with improved statistical significance in the 
model’s predictability [R2Y(cum) = 0.78 and Q2(cum) = 0.60]. As previously 
described [7, 40], we found (Table 2) an increase in -alanine, glycine, taurine 
and succinate concentrations in the ASD group. However, glutamate, formate, 
dimethylamine, trimethylamine N-oxide and hippurate were not found to provide 
any discrimination between our 2 populations (VIP <<1, see supplementary 
information). This may be explained by the improved resolution of 2D NMR spectra 
leading to more precise determination of relevant peaks, and a greater number of 
correlated variables, as VIP is a cumulative vector over all components up to the 
selected one. As in Yap et al.’s study [7], the metabolites that were significantly 
lower for the ASD children were creatine and 3-methylhistidine. However, in 
contrast, in their study, N-methylnicotinamide and N-methylnicotinic acid were not 
observed in the aromatic zone, and for aliphatic protons, chemical shifts were 
outside our range of study (region near water saturation). 
The listing of these potent biomarkers went in the same way as previous 
results obtained by GC/flame ionisation detection (FID) analysis: cystine, histidine, 
tryptophan, and phenylalanine were also in lower concentrations in autistic group 
[41]. Kaluzna-Czaplinska et al. have studied by GC-MS urine of autistic children 
and have described , as shown in this 2D NMR study, an increased in urine of 
autistic children of citric acid [42], and homovanillic acid [43] concentrations, 
and a decrease in tryptophan concentration [44]. Serotonin and -alanine have 
been shown in increase concentration in autistic population by different 
metabolomics studies [8].  
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The results of discriminating biomarkers were validated using univariate 
analysis. One of the main problems of 1H NMR metabolomics studies is the lack of 
significance of the data due to the high degree of variability leading to high 
confidence levels of metabolite concentrations. In a previous 1D 1H NMR study, 
after t-test analysis, the putative biomarkers were not found to be statistically 
significant [7]. Using 2D NMR study, we obtained 7 cross-peaks (Table 2) with 
significant differences at p < 0.05 possibly explained by the better selectivity of 
the technique. 
Compared to this previous 1D 1H NMR study [7], where about 10 metabolites 
were proposed, our 2D HSQC analysis was able to identify 20 discriminating 
features (VIP>1) some of which were assigned and others only characterized by 
their 1H-13C chemical shifts (Table 2). Peaks 93, 114, 123, 131, 134, and 138 were 
at higher levels in the ASD group than in controls. All these cross-peaks should be 
assigned more precisely by further studies.
In this study we showed that 2D HSQC–based NMR analysis was able to 
discriminate between two populations based on their urinary profiles. As many 
metabolites share several common pathways, and because we evaluated the value 
of a 300 MHz magnet for metabolomics study, we only focused on the description 
of the differences between statistically significant metabolites. However further 
studies are necessary to define the specificity and sensitivity of the parameters 
identified.
5. Conclusion 
Urinary screening by NMR spectroscopy for children with neurodevelopment 
disorders such as autism could be a good, non-invasive, and easy tool to assess 
metabolic modifications associated with the disorder. Compared to 1H NMR, 2D 
HSQC NMR provides the opportunity to burst through potentially overlapping 
signals in the 13C dimension, increasing the number of peaks and thus the chance 
to discriminate between populations with different metabolite profiles. Combining 
NMR spectroscopy with multivariate statistical analysis, we were able to 
discriminate between a group of 30 ASD children and a group of typically 
developing children on the basis of their urinary profiles more effectively using 2D 
1H-13C HSQC urinary profiles. Pre-processing data is a critical step in the 
metabolomics workflow. Different scaling methods were evaluated in order to 
obtain the best statistical model. In this study, we showed that a 2D HSQC 
sequence done on a widely available 300 MHz spectrometer could be suitable for 
metabolomics studies. Moreover, although 2D NMR is a little more time 
consuming, NMR HSQC analysis on targeted metabolites of urine samples is a 
potentially useful clinical tool for diagnosis of children with ASD compared to non-
autistic children and may improve the understanding of the pathogenesis of ASD.
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